Home Angiogenesis BTK

BTK Inhibitors

Other Angiogenesis Related Inhibitors

Src FGFR HIF Bcr-Abl Syk VDA FLT3 FAK ANGPTL FLT
Cat.No. Product Name Information Product Use Citations Product Validations
E1993 Catadegbrutinib (BGB-16673) Catadegbrutinib (BGB-16673) is an inhibitor of Bruton’s tyrosine kinase (Btk) and can be used in research for the treatment of autoimmune and inflammatory diseases.
Dissertation, Ulm University, 2026, nan
Dissertation, Ulm University, 2026, Table 2.1.7
S2680 Ibrutinib (PCI-32765) Ibrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
PLoS One, 2026, 21(4):e0337682
Cell Rep Med, 2025, 6(3):102027
J Allergy Clin Immunol, 2025, 155(2):569-582
Verified customer review of Ibrutinib (PCI-32765)
S8116 Acalabrutinib (ACP-196) Acalabrutinib (ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This compound has improved target specificity with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.
J Allergy Clin Immunol, 2025, 155(2):569-582
Cancers (Basel), 2025, 17(11)1889
bioRxiv, 2025, 2025.05.20.655210
Verified customer review of Acalabrutinib (ACP-196)
S7173 Spebrutinib (AVL-292) Spebrutinib (AVL-292) is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. It is in Phase 1.
oparu, 2023, 10.18725/OPARU-47820
Elife, 2021, 10e66984
American Journal of Physiology-Cell Physiology, 2021, C902-C915
Verified customer review of Spebrutinib (AVL-292)
S8166 tirabrutinib(ONO-4059) hydrochloride Tirabrutinib Hydrochloride (ONO-4059, GS-4059) is a highly potent and selective BTK inhibitor with an IC50 of 2.2 nM.
PLoS One, 2023, 18(8):e0290872
Br J Pharmacol, 2022, 179(11):2754-2770
Am J Physiol Cell Physiol, 2021, 320(5):C902-C915
S7734 LFM-A13 LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and IRK.
Journal of Biomedical Science, October 16, 2015, 87
Journal of Clinical Investigation, January 02, 2020, 1793-1807
Br J Pharmacol, 2022, 179(11):2754-2770
Verified customer review of LFM-A13
S7051 CGI1746 CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.
J Allergy Clin Immunol, 2025, 155(2):569-582
bioRxiv, 2024, nan
Elife, 2020, 9e60470
Verified customer review of CGI1746
S8791 Zanubrutinib (BGB-3111) Zanubrutinib is a potent, specific and irreversible BTK inhibitor that has been shown to have a lower off-target inhibitory activity on other kinases, including ITK, JAK3 and EGFR.
bioRxiv, May 10, 2025, nan
Blood Advances, June 11, 2024, 2846-2860
Blood, July 06, 2023, 62-72
S7257 CNX-774 CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.
Cancer Lett, 2023, 552:215981
Cancer Letters, 2023, 215981
Br J Pharmacol, 2022, 179(11):2754-2770
Verified customer review of CNX-774
S8777 Evobrutinib Evobrutinib is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity.
Cancer Res Commun, 2025, 5(9):1621-1630
Brain Pathol, 2024, e13240.
J Leukoc Biol, 2024, qiae160

Signaling Pathway Map